Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Rosa Elena Menjivar

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-1551-869X; OpenAlex author ID A5016242807; NIH RePORTER profile ID 12234541. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 0)
Trials
0
Grants
1
Labs led
0
Collaborators
35
Papers, trials and grants by year

2021: 2 papers, 1 grant · 2022: 1 paper · 2023: 3 papers · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 9

  1. Targeting CCR1 Remodels the Tumor Microenvironment and Relieves Immunosuppression in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-25-1300↗
  2. Multidimensional analyses identify genes of high priority for pancreatic cancer research. Co-author DOI 10.1172/jci.insight.174264↗
  3. Notch Signaling Regulates Immunosuppressive Tumor-Associated Macrophage Function in Pancreatic Cancer. First author DOI 10.1158/2326-6066.cir-23-0037↗
  4. Uridine-derived ribose fuels glucose-restricted pancreatic cancer. Co-author DOI 10.1038/s41586-023-06073-w↗
  5. WNT signaling in the tumor microenvironment promotes immunosuppression in murine pancreatic cancer. First author DOI 10.1084/jem.20220503↗
  6. Arginase 1 is a key driver of immune suppression in pancreatic cancer. Co-author DOI 10.7554/elife.80721↗
  7. Combinatorial Gli activity directs immune infiltration and tumor growth in pancreatic cancer. Co-author DOI 10.1371/journal.pgen.1010315↗
  8. Nutrient profiling reveals extracellular uridine as a fuel for pancreatic cancer through uridine phosphorylase 1 Co-author DOI 10.1101/2021.06.07.447448↗
  9. Apolipoprotein E Promotes Immune Suppression in Pancreatic Cancer through NF-κB-Mediated Production of CXCL1. Co-author DOI 10.1158/0008-5472.can-20-3929↗

Grants 1

  1. Myeloid cell driven immune suppression in pancreatic cancer F31CA257533↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marina Pasca di Magliano · 9 shared papers, 2021–2026 · strength 1.34
  2. Eileen S. Carpenter · 7 shared papers, 2021–2026 · strength 1.02
  3. Zeribe C. Nwosu · 7 shared papers, 2021–2026 · strength 1.00
  4. Costas Andreas Lyssiotis · 6 shared papers, 2021–2026 · strength 0.88
  5. Katelyn L. Donahue · 5 shared papers, 2021–2026 · strength 0.78
  6. Filip Bednar · 4 shared papers, 2022–2026 · strength 0.64
  7. Nina G. Steele · 4 shared papers, 2021–2025 · strength 0.60
  8. Yaqing Zhang · 3 shared papers, 2023–2026 · strength 0.54
  9. Padma Kadiyala · 3 shared papers, 2023–2026 · strength 0.50
  10. Wenting Du · 3 shared papers, 2023–2024 · strength 0.48
  11. Samantha B. Kemp · 3 shared papers, 2021–2025 · strength 0.48
  12. Christopher J. Halbrook · 3 shared papers, 2021–2023 · strength 0.38
  13. Wei Yan · 2 shared papers, 2024–2026 · strength 0.37
  14. Yaqing Zhang · 3 shared papers, 2021–2023 · strength 0.37
  15. Howard C. Crawford · 3 shared papers, 2021–2023 · strength 0.37
  16. Daniel James Salas-Escabillas · 2 shared papers, 2022–2023 · strength 0.26
  17. Matthew H. Ward · 2 shared papers, 2021–2023 · strength 0.24
  18. Anguraj Sadanandam · 2 shared papers, 2021–2023 · strength 0.24
  19. Li Zhang · 2 shared papers, 2021–2023 · strength 0.24
  20. Heather Marie Giza · 1 shared paper, 2025 · strength 0.20
  21. Ian M. Loveless · 1 shared paper, 2025 · strength 0.20
  22. Emily L. Lasse Opsahl · 1 shared paper, 2026 · strength 0.20
  23. Dominik Awad · 1 shared paper, 2026 · strength 0.20
  24. Ahmed M. Elhossiny · 1 shared paper, 2026 · strength 0.20
  25. Timothy L. Frankel · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.